Design and Synthesis of Novel Celastrol Derivatives as Potential Anticancer Agents against Gastric Cancer Cells. 2022

Zhi-Chao Lei, and Na Li, and Nai-Rong Yu, and Wei Ju, and Xiao-Na Sun, and Xue-Ling Zhang, and Hai-Juan Dong, and Jian-Bo Sun, and Li Chen
State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, People's Republic of China.

Gastric cancer (GC) is a common malignant disease worldwide, and finding novel agents and strategies for the treatment of GC are of urgent need. Celastrol (CEL) is a well-known natural product with antineoplastic activity. In this study, pyrazole analogues were introduced at the C-29 position of CEL. A total of 24 new derivatives were designed, synthesized, and evaluated for their mechanism and antitumor activity in vitro and in vivo. Among them, compound 21 exhibited the best activity against BGC-823 cells (IC50 = 0.21 ± 0.01 μM). Further biological studies showed that 21 significantly raised the reactive oxygen species (ROS) levels to activate the apoptotic pathway, causing mitochondrial dysfunction in BGC-823 cells. In addition, 21 also arrested cells in the G2/M phase to induce tumor cell apoptosis. In a nude mouse tumor xenograft model, 21 exhibited a better tumor inhibition rate (89.85%) than CEL (inhibition rate 76.52%). Taken together, the present study has provided an anticancer lead compound candidate, 21, and has revealed that increased ROS generation may be an effective strategy in the treatment of GC.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide
D013876 Thiophenes A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur. Thiophene
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Zhi-Chao Lei, and Na Li, and Nai-Rong Yu, and Wei Ju, and Xiao-Na Sun, and Xue-Ling Zhang, and Hai-Juan Dong, and Jian-Bo Sun, and Li Chen
May 2015, European journal of medicinal chemistry,
Zhi-Chao Lei, and Na Li, and Nai-Rong Yu, and Wei Ju, and Xiao-Na Sun, and Xue-Ling Zhang, and Hai-Juan Dong, and Jian-Bo Sun, and Li Chen
December 2017, Journal of enzyme inhibition and medicinal chemistry,
Zhi-Chao Lei, and Na Li, and Nai-Rong Yu, and Wei Ju, and Xiao-Na Sun, and Xue-Ling Zhang, and Hai-Juan Dong, and Jian-Bo Sun, and Li Chen
January 2022, Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents,
Zhi-Chao Lei, and Na Li, and Nai-Rong Yu, and Wei Ju, and Xiao-Na Sun, and Xue-Ling Zhang, and Hai-Juan Dong, and Jian-Bo Sun, and Li Chen
April 2014, Bioorganic chemistry,
Zhi-Chao Lei, and Na Li, and Nai-Rong Yu, and Wei Ju, and Xiao-Na Sun, and Xue-Ling Zhang, and Hai-Juan Dong, and Jian-Bo Sun, and Li Chen
August 2014, European journal of medicinal chemistry,
Zhi-Chao Lei, and Na Li, and Nai-Rong Yu, and Wei Ju, and Xiao-Na Sun, and Xue-Ling Zhang, and Hai-Juan Dong, and Jian-Bo Sun, and Li Chen
June 2021, Bioorganic chemistry,
Zhi-Chao Lei, and Na Li, and Nai-Rong Yu, and Wei Ju, and Xiao-Na Sun, and Xue-Ling Zhang, and Hai-Juan Dong, and Jian-Bo Sun, and Li Chen
February 2016, Bioorganic & medicinal chemistry letters,
Zhi-Chao Lei, and Na Li, and Nai-Rong Yu, and Wei Ju, and Xiao-Na Sun, and Xue-Ling Zhang, and Hai-Juan Dong, and Jian-Bo Sun, and Li Chen
September 2019, Molecules (Basel, Switzerland),
Zhi-Chao Lei, and Na Li, and Nai-Rong Yu, and Wei Ju, and Xiao-Na Sun, and Xue-Ling Zhang, and Hai-Juan Dong, and Jian-Bo Sun, and Li Chen
July 2014, Molecules (Basel, Switzerland),
Zhi-Chao Lei, and Na Li, and Nai-Rong Yu, and Wei Ju, and Xiao-Na Sun, and Xue-Ling Zhang, and Hai-Juan Dong, and Jian-Bo Sun, and Li Chen
April 2024, Chemistry & biodiversity,
Copied contents to your clipboard!